This study highlighted the drug’s ability to inhibit tumor growth, although associated toxicities were observed, necessitating further research to optimize its therapeutic window.

Due to its lipophilic properties, crisnatol can effectively penetrate the blood-brain barrier, making it a potential treatment for brain tumors.

[citation needed] Crisnatol has undergone several Phase I and II clinical trials aimed at determining its pharmacokinetics, safety profile, and efficacy against various types of solid tumors.

In one Phase I trial, crisnatol mesylate was administered as a protracted infusion in patients with advanced solid malignancies, revealing a manageable toxicity profile and some evidence of tumor regression.

The ability of crisnatol to cross the blood-brain barrier has led to interest in its use against brain cancers, although further studies are needed to fully establish its efficacy and safety in this context.